Not yet recruitingInterventionalPhase 1Last updated Aug 13, 2026

A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata

A Phase I Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata

Overview

ClinicalTrials.gov ID: NCT07762443
Lead Sponsor: Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY
Brief Summary: This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Sep 30, 2026Estimated
Primary Completion Date: Dec 30, 2027Estimated
Completion Date: Dec 30, 2027Estimated

Study Record Dates

First Submitted: Aug 9, 2026
First Submitted that Met QC Criteria: Aug 9, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 9, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Aug 2026

NCT07749716Not yet recruiting

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

NCT07329101Completed

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

NCT06009094Completed

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

NCT07172347Recruiting

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

NCT05997927Completed

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT06826196Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata